Delivery Order SPE2DB25D3017-SPE2DB25FVJYP
- Not listed
- The Defense Logistics Agency awarded a Delivery Order valued at $47,056.22 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 MG tablets (30-count units). This firm fixed-price contract, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. The pharmaceutical product will be delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at approximately $60,000 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This competitively awarded, firm fixed-price delivery order was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition...
- The Defense Logistics Agency awarded a delivery order valued at $18,060.83 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,153.60 to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the pharmaceutical supply chain support that...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,579.01 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, awarded on August 14, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,774.90 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and is to be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded transaction for pharmaceutical supplies to support...
- The Defense Logistics Agency awarded a delivery order valued at $3,326.60 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count). The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance is scheduled to conclude by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,100.80 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $4,931.21 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVJYPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $56,310.03 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA's medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The oncolytic medication being procured under this delivery order supports the Defense Health Agency and other government healthcare systems' operational requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.3k | 7/23/25 |